About
Serial entrepreneur/scientist (a weird combination :-p) in biotech with a strong focus on…
Activity
-
Grateful to be coordinating PHARMECO alongside a perfect consortium of dedicated partners. Together, we’re not just imagining a sustainable future…
Grateful to be coordinating PHARMECO alongside a perfect consortium of dedicated partners. Together, we’re not just imagining a sustainable future…
Liked by Jeroen Hofenk
-
A problem we intend to solve in 2025! Merry Christmas and Happy Holidays everyone!
A problem we intend to solve in 2025! Merry Christmas and Happy Holidays everyone!
Liked by Jeroen Hofenk
Experience
Patents
-
NANO-ADJUVANT FORMULATIONS AND METHODS OF USE THEREOF
Issued BE EP20202867.6
The patent relates to novel nano adjuvants, an influenza vaccine containing the nano adjuvants and a preparation method of the adjuvants. The compositions comprise a plurality of combinatorial nano-particles in a pharmaceutically acceptable carrier. When administered with antigen(s) to mammal results in enhanced immunogenicity of antigen. The enhanced immunogenicity manifests as cell mediated immunity. The adjuvants are seen with variety of antigens in various mammals irrespective of their…
The patent relates to novel nano adjuvants, an influenza vaccine containing the nano adjuvants and a preparation method of the adjuvants. The compositions comprise a plurality of combinatorial nano-particles in a pharmaceutically acceptable carrier. When administered with antigen(s) to mammal results in enhanced immunogenicity of antigen. The enhanced immunogenicity manifests as cell mediated immunity. The adjuvants are seen with variety of antigens in various mammals irrespective of their immune status at the time of administration with the adjuvant and antigen containing composition, e.g. immune naïve or preimmunized status.
-
GENIPIN-CROSSLINKED PDRN-SACRAN BIOPOLYMER SCAFFOLDS
Filed BE EP20163463.1
The patent relates to novel anti-inflammatory biopolymer composition for applications in oral hygiene products, wound-care, cosmetics, pharmaceuticals, and food, or can be used as mucoadhesive carrier of APIs. Said invention is particularly useful in the treatment of inflammatory gum diseases, and moreover in the use as a wound healing agent. The novel biopolymers of present invention are PDRN-genipin-Sacran scaffolds, PDRN-Genipin scaffolds, or Sacran-Genipin Scaffolds, whereas genipin…
The patent relates to novel anti-inflammatory biopolymer composition for applications in oral hygiene products, wound-care, cosmetics, pharmaceuticals, and food, or can be used as mucoadhesive carrier of APIs. Said invention is particularly useful in the treatment of inflammatory gum diseases, and moreover in the use as a wound healing agent. The novel biopolymers of present invention are PDRN-genipin-Sacran scaffolds, PDRN-Genipin scaffolds, or Sacran-Genipin Scaffolds, whereas genipin functions as a natural crosslinker.
-
TRANS-COMPLEMENTARY VECTOR SYSTEM FOR HIGHLY EFFICIENT HETEROLOGOUS GENE EXPRESSION IN PLANTS
Filed EP23166367
The invention relates to a trans-complementary system for heterologous expression of genes in plants and comprises a producer vector and a helper vector whereas I) said producer vector is incapable for at least one function needed to cause systemic infection in plants e.g., either by replication, cell-to-cell and/or long distance movement, and II) the helper vector completes the missing function in tandem. Certain producer and helper vectors in one trans-complementary system are derived from…
The invention relates to a trans-complementary system for heterologous expression of genes in plants and comprises a producer vector and a helper vector whereas I) said producer vector is incapable for at least one function needed to cause systemic infection in plants e.g., either by replication, cell-to-cell and/or long distance movement, and II) the helper vector completes the missing function in tandem. Certain producer and helper vectors in one trans-complementary system are derived from the same virus, or certain producer and helper vectors in one trans-complementary system are derived from different plant viruses. The present invention also provides methods of use, e.g., to improved yield of the heterologous proteins expressed notably in crop plants, and the ease of use of said system.
-
Novel recombinant spider silk-reinforced collagen proteins produced in plants and the use thereof
Filed EP22166454.3
The invention relates to novel non-naturally occuring, elastomeric animal-free recombinant fusion biopolymers produced in plants through transient expression. The invention comprises encoding fusion proteins of a non-human scleroprotein with a human collagen, capable of forming hydroxylated triple helix fibers.
-
NOVEL SELECTIVE ANTIMICROBIAL FUSION PEPTIDES
Filed EU EP21154190
The patent relates to novel antimicrobial fusion peptides; pharmaceutical compositions comprising the peptides and to uses thereof for treatment or prevention of bacterial infections. The peptides of the present invention are nonhemolytic, exhibit reduced in vitro cytotoxicity relative to other antimicrobial peptides, which makes them useful in pharmaceutical, healthcare, medical device, food, and personal care applications.
-
NAV1.7 SPECIFIC INHIBITOR AGENT WITH IMPROVED ANALGESIA AND PERIPHERAL DELIVERY
Filed EU EP20202846.0
The patent relates to novel recombinant fusion toxin analogues with improved lipid
membrane interactions, potency for the analgesic sodium channels NaV1.7 and NaV1.8, and peripheral delivery. The fusion protein is produced
through transiently transformed Nicotiana Benthamiana plants. The patent provides
methods and pharmaceutical compositions for therapeutic pain management, either via parenteral, oral, nasal, bronchial, or topical administration. -
INTRANASAL COMPOSITION FOR IMPROVED DELIVERY OF ANTIGENS
Filed EU EP20202854
The patent relates to novel vaccine formulations designed for mucosal delivery to the nasal-associated lymphoid tissue, via intranasal administration in various mammals irrespective of their immune status at the time of administration with the adjuvant and antigen containing composition, e.g. immune naïve or preimmunized status. . The association of antigens with mucosal adjuvants and delivery systems is emphasized.
-
PRODUCING ISOTHIOCYANATES FROM CALLUS SUSPENSION CULTURES
Filed EU WO2020182853
a method of producing isothiocyanates, The method comprises forming, in a semi-solid or solid callus induction medium, compact callus aggregates from cells obtained from explant material of a Brassica oleracea L. plant. The method comprises transferring cells from the callus aggregates, e.g. transferring the callus aggregates, to a suspension culture in a liquid medium in a shake flask, the liquid medium containing a plurality of elicitors. The method comprises transferring, after culturing in…
a method of producing isothiocyanates, The method comprises forming, in a semi-solid or solid callus induction medium, compact callus aggregates from cells obtained from explant material of a Brassica oleracea L. plant. The method comprises transferring cells from the callus aggregates, e.g. transferring the callus aggregates, to a suspension culture in a liquid medium in a shake flask, the liquid medium containing a plurality of elicitors. The method comprises transferring, after culturing in the shake flask, cells from the suspension culture to a further suspension culture in a bioreactor containing the elicitors. The method comprises extracting and/or purifying of at least one isothiocyanate from cells obtained from the bioreactor. The elicitors comprise chitosan and salicylic acid to increase accumulation of benzyl isothiocyanate or any other isothiocyanate.
-
CANNABINOID PRECURSOR PRODUCTION
Filed EU WO2020182866
A nucleic acid molecule is disclosed for transiently transforming a plant to produce Δ9-tetrahydrocannabinolic acid synthase, cannabidiolic acid synthase, and/or cannabichromenic acid synthase and a viral vector comprising such nucleic acid molecule, and to methods for producing THCAS, CBDAS, CBCAS, THCA, CBDA, CBCA, THC, CBD and/or CBC based on transient expression of the nucleic acid sequence in a host plant.
-
TRANSCRIPTION FACTOR-MEDIATED PROMOTION OF DIRECT SOMATIC EMBRYOGENESIS
Filed EU WO2020182857
A recombinant protein for use in a liquid culture medium for photo-autotrophic micropropagation of Cannabis Sativa L. is disclosed. The recombinant protein comprises a fusion of a growth induction part and a uptake enhancement part. The growth induction part comprises an Arabinogalactan protein and/or a plant transcription factor associated with plant growth and development. The uptake enhancement part comprises a cell penetrating peptide sequence and a nuclear localization signal encoded by…
A recombinant protein for use in a liquid culture medium for photo-autotrophic micropropagation of Cannabis Sativa L. is disclosed. The recombinant protein comprises a fusion of a growth induction part and a uptake enhancement part. The growth induction part comprises an Arabinogalactan protein and/or a plant transcription factor associated with plant growth and development. The uptake enhancement part comprises a cell penetrating peptide sequence and a nuclear localization signal encoded by the peptide sequence
-
REPAIR OF UV-INDUCED DNA LESIONS
EU WO2020120788
(EN)
A composition comprising a recombinant enzyme that comprises a fusion of: a cyclobutane pyrimidine dimer photolyase, a pyrimidine(6-4)pyrimidone photolyase, and a skin penetrating peptide for the repair of pre-mutagenic DNA lesions induced by UV radiation.
-
SULFORAPHANE-MELATONIN-LIKE COMPOUND
EU WO2020043748
A composition comprising a compound that comprises or consists of a conjugation of 6-hydroxymelatonin and 6- methylsufinylhexyl isothiocyanate is disclosed, as well as this composition for the use as a medicament. Furthermore, this composition for the use in a method of treating and/or preventing an epithelial tissue disease and/or disorder is disclosed.
Honors & Awards
-
A sustainable first-in-class multitargeted immunotherapy for the treatment of prostate cancer
VLAIO
Together with CimCure B.V. and Amsterdam UMC, SwiftPharma has secured a €1.1 million Eurostars grant for the development of a plant-made multi-targeted vaccination-based immunotherapy for prostate cancer. SwiftPharma obtained a contribution by VLAIO for EURO 321.172 (Grant number HBC.2024.0303)
-
PharmECO - Advancing Safe and Sustainable by Design Practices in Pharmaceutical Manufacturing
Innovative Health Initiative (IHI JU Call 4, Topic 6)
This trailblazing 41 million Euro grant, co-funded under the Innovative Health
Initiative (IHI JU Call 4, Topic 6), is focused on revolutionizing pharmaceutical manufacturing by (i)
implementing cutting-edge, sustainable, and scalable manufacturing technologies, and (ii)
establishing harmonized environmental sustainability assessment systems for
pharmaceuticals and biopharmaceuticals.
To achieve the ambitious goals of this project, SwiftPharma joins forces with 30
esteemed…This trailblazing 41 million Euro grant, co-funded under the Innovative Health
Initiative (IHI JU Call 4, Topic 6), is focused on revolutionizing pharmaceutical manufacturing by (i)
implementing cutting-edge, sustainable, and scalable manufacturing technologies, and (ii)
establishing harmonized environmental sustainability assessment systems for
pharmaceuticals and biopharmaceuticals.
To achieve the ambitious goals of this project, SwiftPharma joins forces with 30
esteemed international partners, including universities, research institutes, governmental
bodies, SMEs, and major pharmaceutical companies, each bringing their unique expertise.
SwiftPharma will play a crucial role in the PharmECO project by providing valuable insights into the sustainability assessment of plant-based biomanufacturing through the scaling of its HyperXpress transient expression technology. The company will collaborate with industry partners to produce three of its model proteins: an antiviral lectin, a monoclonal antibody biosimilar, and a prostate cancer vaccine across different expression platforms. By comparing sustainability hotspots—specific areas within a system, process, product lifecycle, or supply chain that have significant environmental, social, or economic impacts—SwiftPharma aims to identify and prioritize actions and resources to effectively enhance sustainability performance. -
Beta-Globin Gene Correction Using Peptide Nucleic Acids For The Treatment Of Sickle Cell Anemia
NIH : NHLBI
Acknowledged support of the NIH : NHLBI under the SBIR program for $228.490 to test the feasibility of using triplex-forming oligonucleotides to correct the sickle cell disease (SCD) mutation in human CD34+ cells. This technology constituted minimally invasive gene repair, as gene modification occurs in situ via use of the cell's own DNA repair machinery, without the need for viral vectors.
Languages
-
Nederlands
Native or bilingual proficiency
-
Engels
Full professional proficiency
-
Frans
Elementary proficiency
-
Duits
Elementary proficiency
More activity by Jeroen
-
AAV helper plasmids are too big. That means they cost more / are less safe. This paper shows how to solve the issue. What the authors did: They…
AAV helper plasmids are too big. That means they cost more / are less safe. This paper shows how to solve the issue. What the authors did: They…
Liked by Jeroen Hofenk
-
We are excited to welcome Dr. Mark Gontsarik as the new Project Manager at CESPE, Centre of Excellence in Sustainable Pharmaceutical Engineering and…
We are excited to welcome Dr. Mark Gontsarik as the new Project Manager at CESPE, Centre of Excellence in Sustainable Pharmaceutical Engineering and…
Liked by Jeroen Hofenk
-
Yeay! It's officially out - to all of you who have been looking for the ONE... AAV antibody it's here! Detects multiple serotypes including novel…
Yeay! It's officially out - to all of you who have been looking for the ONE... AAV antibody it's here! Detects multiple serotypes including novel…
Liked by Jeroen Hofenk
-
🔴 The Commission approves €52 million Slovenian State aid measure to support Lek Pharmaceuticals' production of biological drug substances 💉 💊…
🔴 The Commission approves €52 million Slovenian State aid measure to support Lek Pharmaceuticals' production of biological drug substances 💉 💊…
Liked by Jeroen Hofenk
-
This week, Knappe Koppen on VRT took a deep dive into the fascinating world of nanobodies, showcasing the pioneering work of the late Raymond Hamers…
This week, Knappe Koppen on VRT took a deep dive into the fascinating world of nanobodies, showcasing the pioneering work of the late Raymond Hamers…
Liked by Jeroen Hofenk
-
💸 𝐖𝐡𝐚𝐭 𝐚𝐫𝐞 𝐭𝐡𝐞 𝐭𝐨𝐩 𝐫𝐞𝐯𝐞𝐧𝐮𝐞 𝐠𝐞𝐧𝐞𝐫𝐚𝐭𝐨𝐫𝐬 𝐟𝐨𝐫 𝐩𝐡𝐚𝐫𝐦𝐚? The pharmaceutical industry continues to demonstrate…
💸 𝐖𝐡𝐚𝐭 𝐚𝐫𝐞 𝐭𝐡𝐞 𝐭𝐨𝐩 𝐫𝐞𝐯𝐞𝐧𝐮𝐞 𝐠𝐞𝐧𝐞𝐫𝐚𝐭𝐨𝐫𝐬 𝐟𝐨𝐫 𝐩𝐡𝐚𝐫𝐦𝐚? The pharmaceutical industry continues to demonstrate…
Liked by Jeroen Hofenk
-
The BIC Team is out in Brussels this evening getting into the holiday spirit 🎄Dirk Carrez, Samuele Ambrosetti, Marco Rupp, Nelo Emerencia, Sophia De…
The BIC Team is out in Brussels this evening getting into the holiday spirit 🎄Dirk Carrez, Samuele Ambrosetti, Marco Rupp, Nelo Emerencia, Sophia De…
Liked by Jeroen Hofenk
Other similar profiles
Explore collaborative articles
We’re unlocking community knowledge in a new way. Experts add insights directly into each article, started with the help of AI.
Explore More